Skip to main content
. 2019 Mar 20;20(6):1396. doi: 10.3390/ijms20061396

Figure 1.

Figure 1

β2-adrenergic receptor (AR) inhibits aldosterone-induced osteopontin (OPN) upregulation in H9c2 cardiomyocytes. H9c2 cells were treated with 10 nM aldosterone (Aldo), 10 µM salbutamol (Sal), or 10 nM aldosterone in the presence of 10 µM salbutamol (Sal+Aldo) for 2 h. At the end of this 2-h period, cells were harvested, total RNA isolated, and real-time PCR for OPN mRNA quantitation was performed. *, p < 0.05, vs. any other treatment; n = 4 independent experiments/condition.